, Volume 17, Issue 3, pp 189–196 | Cite as

The antimicrobial activity of lactoferrin: Current status and perspectives

  • Nicola Orsi


Lactoferrin (Lf) is a multifunctional iron glycoprotein which is known to exert a broad-spectrum primary defense activity against bacteria, fungi, protozoa and viruses. Its iron sequestering property is at the basis of the bacteriostatic effect, which can be counteracted by bacterial pathogens by two mechanisms: the production of siderophores which bind ferric ion with high affinity and transport it into cells, or the expression of specific receptors capable of removing the iron directly from lactoferrin at the bacterial surface. A particular aspect of the problem of iron supply occurs in bacteria (e.g. Legionella) which behave as intracellular pathogens, multiplying in professional and non professional macrophages of the host. Besides this bacteriostatic action, Lf can show a direct bactericidal activity due to its binding to the lipid A part of bacterial LPS, with an associated increase in membrane permeability. This action is due to lactoferricin (Lfc), a peptide obtained from Lf by enzymatic cleavage, which is active not only against bacteria, but even against fungi, protozoa and viruses. Additional antibacterial activities of Lf have also been described. They concern specific effects on the biofilm development, the bacterial adhesion and colonization, the intracellular invasion, the apoptosis of infected cells and the bactericidal activity of PMN. The antifungal activity of Lf and Lfc has been mainly studied towards Candida, with direct action on Candida cell membranes. Even the sensitivity of the genus tricophyton has been studied, indicating a potential usefulness of this molecule. Among protozoa, Toxoplasma gondii is sensitive to Lf, both in vitro and in vivo tests, while Trichomonads can use lactoferrin for iron requirements. As to the antiviral activity, it is exerted against several enveloped and naked viruses, with an inhibition which takes place in the early phases of viral invection, as a consequence of binding to the viral particle or to the cell receptors for virus. The antiviral activity of Lf has also been demonstrated in in vivo model invections and proposed for a selective delivery of antiviral drugs. The new perspectives in the studies on the antimicrobial activity of Lf appear to be linked to its potential prophylactic and therapeutical use in a considerable spectrum of medical conditions, taking advantage of the availability of the recombinant human Lf. But the historical evolution of our knowledge on Lf indicates that its antimicrobial activity must be considered in a general picture of all the biological properties of this multifunctional protein.


Antimicrobial Activity Antiviral Activity Defense Activity Bacteriostatic Action Bacteriostatic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ajello M, Greco R, Giansanti F, Massucci MT, Antonini G, Valenti P. 2002 Anti-invasive activity of bovine lactoferrin towards group A streptococci. Biochem Cell Biol 80, 119-124.PubMedGoogle Scholar
  2. Andersen JH, Osbakk SA, Vorland LH, Traavik T, Gutteberg TJ. 2001 Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res 51, 141-149.PubMedGoogle Scholar
  3. Antonini E, Orsi N, Valenti P. 1977 Effetto delle transferrine sulla patogenicitá delle Enterobacteriaceae. G Mal Infett Parassit 29, 481-489.Google Scholar
  4. Appelmelk BJ, An YK, Geerts M et al. 1994 Lactoferrin is a lipid A-binding protein. Infect Immun 62, 2628-2632.PubMedGoogle Scholar
  5. Arnold RR, Cole MF, Mcghee JR. 1977 A bactericidal effect for human lactoferrin. Science 197, 263-265.PubMedGoogle Scholar
  6. Arnold D, Di Biase AM, Marchetti M et al. 2002 Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res 53, 153-158.PubMedGoogle Scholar
  7. Bellamy W, Takase M, Wakabayashi H, Kavase K, Tomita M. 1992 Antibacterial spectrum of lactoferricin B, a potent bactericide peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73, 472-479.PubMedGoogle Scholar
  8. Bellamy W, Wakabayashi H, Takase M, Kavase K, Shinamura S, Tomita M. 1993 Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 182, 97-105.PubMedGoogle Scholar
  9. Blanton KJ, Biswas GD, Tsai J et al. 1990 Genetic evidence that Neisseria gonorrhoeae produces specific receptors for transferrin and lactoferrin. J Bacteriol 172, 5225-5235.PubMedGoogle Scholar
  10. Brandenburg K, Jurgens G, Muller M, Fukuoka S, Koch MHJ. 2001 Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 382, 1215-1225.PubMedGoogle Scholar
  11. Braun V, Killmann H. 1999 Bacterial solutions to the iron supply problem. Trends Biochem Sci 24, 104-109.PubMedGoogle Scholar
  12. Brock JH. 2002 The physiology of lactoferrin. Biochem Cell Biol 80, 1-6.Google Scholar
  13. Bullen JJ, Rogers HJ, Leigh L. 1972 Iron binding proteins in milk and resistance to Escherichia coli infection in infants. Br Med J 1, 68-75.Google Scholar
  14. Byrd TF, Horwitz MA. 1989 Interferon gamma-activated human monocytes down regulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 83, 1457-1465.PubMedGoogle Scholar
  15. Byrd TF, Horwitz MA. 1991 Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in non activated and interferon gamma-activated monocytes depending upon its degree of iron saturation. J Clin Invest 88, 1103-1112.PubMedGoogle Scholar
  16. Cintra WM, Silva-Filho FC, De Souza W. 1986 The surface charge of Toxoplasma gondii: a cytochemical and electrophoretic study. J Submicrosc Cytol 18, 773-781.PubMedGoogle Scholar
  17. Cirioni O, Giacometti A, Barchiesi F, Scalise G. 2000 Inhibition of growth of Pneumocystis carini by lactoferrin alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46, 577-582.PubMedGoogle Scholar
  18. Conte MP, Longhi C, Petrone G et al. 1999 The anti-invasive effect of bovine lactoferrin requires an interaction with surface proteins of Listeria monocytogenes. Int J Immunopathol Pharmacol 12, 149-155.PubMedGoogle Scholar
  19. Dalmastri C, Valenti P, Visca P, Vittorioso P, Orsi N. 1988 Enhanced antimicrobial activity of lactoferrin by binding to the bacterial surface. Microbiologica 11, 225-230.PubMedGoogle Scholar
  20. Dial EJ, Lichtenberger LM. 2002 Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 80, 113-117.PubMedGoogle Scholar
  21. Di Biase AM, Pietrantoni A, Tinari A et al. 2003 Heparin interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J Med Virol 69, 495-502.PubMedGoogle Scholar
  22. Dolby JM, Stephens S. 1983 Antibodies to Escherichia coli O antigens and the in-vitro bacteriostatic properties of human milk and its IgA. Acta Paediatr Scand 72, 577-582.PubMedGoogle Scholar
  23. Ellison RT III, Giehl T. 1991 Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88, 1080-1091.PubMedGoogle Scholar
  24. Ellison RT III, Giehl TJ, La Force FM. 1988 Damage of the outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56, 2774-2781.PubMedGoogle Scholar
  25. Ellison RT III, La Force M, Giehl TJ, Boose D, Dunn BE. 1990 Lactoferrin and transferrin damage of the Gram-negative outer membrane is modulated by Ca 2+ and Mg 2+. J Gen Microbiol 136, 1437-1446.PubMedGoogle Scholar
  26. Fujihara T, Hayashi K. 1995 Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch Virol 140, 1469-1472.PubMedGoogle Scholar
  27. Goldoni P, Sinibaldi L, Valenti P, Orsi N. 2000 Metal complexes of lactoferrin and their effect on the intracellular multiplication of Legionella pneumophila. Biometals 13, 15-22.PubMedGoogle Scholar
  28. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. 2003 Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis 187, 87-95.PubMedGoogle Scholar
  29. Grover M, Giouzeppos O, Schnagel RD, May JT.1997 Effect of human milk prostaglandins and lactoferrin on respiratory syncityal virus and rotavirus Acta Paediatr 86, 315-316.PubMedGoogle Scholar
  30. Hara K, Ikeda M, Saito S et al. 2002 Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24, 228.PubMedGoogle Scholar
  31. Harmsen MC, Swart PJ, de Bethune MP et al. 1995 Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172, 380-388.PubMedGoogle Scholar
  32. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. 1994 Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn JMed Sci Biol 47, 73-85.Google Scholar
  33. Hendrixson DR, Qiu J, Shewry SC et al. 2003 Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol Microbiol 47, 607-617.PubMedGoogle Scholar
  34. Hwang PM, Zhon N, Shan X, Arrowsmith CH, Vogel HJ. 1998 Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37, 4288-4298.PubMedGoogle Scholar
  35. Ikeda M, Sugiyama K, Tanaka T et al. 1998 Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245, 549-553.PubMedGoogle Scholar
  36. Isamida T, Tanaka T, Omata Y, Yamauchi K, Shimazachi K, Saiko A. 1998 Protective effect of lactoferrin against Toxoplasma gondii infection in mice. J Vet Med Sci 60, 241-244.PubMedGoogle Scholar
  37. Iwasa M, Kaito M, Ikoma J et al. 2002 Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 97, 766-767.PubMedGoogle Scholar
  38. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. 1996 Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348, 1523-1524.Google Scholar
  39. Kuipers M, de Vries HG, Eikelboom MC, Meijer DKF, Swart PJ. 1999 Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 43, 2635-2641.PubMedGoogle Scholar
  40. Lehker MW, Alderete JF. 1992 Iron regulates growth of Trichomonas vaginalis and the expression of immunogenic trichomonad protein. Mol Microbiol 6, 123-132.PubMedGoogle Scholar
  41. Leitch EC, Willcox MDF. 1998 Synergic antistaphylococcal properties of lactoferrin and lysozyme. J Med Microbiol 47, 837-842.PubMedGoogle Scholar
  42. Levay PF, Viljoen M. 1995 Lactoferrin: a general review. Haematologica 80, 252-267.PubMedGoogle Scholar
  43. Liles MR, Scheel TA, Cianciotto NP. 2000 Discovery of a nonclassical siderophore, legiobactin, produced by strains of Legionella pneumophila. J Bacteriol 183, 749-757.Google Scholar
  44. Lin TY, Chu C, Chiu CH. 2002 Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis 186, 1161-1164.PubMedGoogle Scholar
  45. Longhi C, Conte MP, Seganti L, Polidoro M, Alfsen A, Valenti P. 1993 Influence of lactoferrin on the entry process of Escherichia coli HB101 (pRI203) in HeLa cells. Med Microbiol Immunol 182, 25-35.PubMedGoogle Scholar
  46. Lonnerdal B, Iyer S. 1995 Lactoferrin: molecular structure and biological function. Annu Rev Nutr 15, 93-110.PubMedGoogle Scholar
  47. Lu L, Hangoc G, Oliff A, Chen LT, Shen RN, Broxmeyer HE. 1987 Protective influence of lactoferrin on mice infected with the polycythemia-inducing strain of Friend virus complex. Cancer Res 47, 4184-4188.PubMedGoogle Scholar
  48. Marchetti M, Superti F. 2001 Antiviral activity of lactoferrin. In: Pandalai SG, ed. Recent developments in antiviral research. Trivandrum: Transworld Research Network: 1, 193-203.Google Scholar
  49. Marchetti M, Superti F, Ammendolia MG, Rossi O, Valenti P, Seganti L. 1999 Inhibition of poliovirus type 1 infection by iron-, manganese-and zinc-saturated lactoferrin. Med Microbiol Immunol 187, 199-204.PubMedGoogle Scholar
  50. Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. 2000 In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol 145, 1571-1582.PubMedGoogle Scholar
  51. Omata Y, Satake M, Maeda R et al. 2001 Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. J Vet Med Sci 63, 187-190.PubMedGoogle Scholar
  52. Orsi N, Valenti P, Visca P. 1988 Attivitá antimicrobica delle transferrine e ruolo di esse nell'immunitá naturale. Ig Mod 89, 612-626.Google Scholar
  53. Plaut AG, Qiu J, St Geme JW. 2000 Human lactoferrin proteolitic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. Vaccine 8, S148-152.Google Scholar
  54. Qiu J, Hendrixson DR, Baker EN, Murphy TF, St Gene JW III, Plaut AG. 1998 Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci USA 95, 12641-12646.PubMedGoogle Scholar
  55. Rainard P. 1993 Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology 79, 648-652.PubMedGoogle Scholar
  56. Ratledge C, Dover LG. 2000 Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 54, 881-941.PubMedGoogle Scholar
  57. Schryvers AB and Lee BC. 1989 Comparative analysis of the transferrin and lactoferrin binding proteins in the family Neisseriaceae. Can J Microbiol 35, 409-415.PubMedGoogle Scholar
  58. Shimizu K, Matsuzawa H, Okada K et al. 1996 Lactoferrin mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Arch Virol 141, 1875-1889.PubMedGoogle Scholar
  59. Siciliano R, Rega B, Marchetti M, Seganti L, Antonini G, Valenti P. 1999 Bovine lactoferrin peptidic fragments involved in the inhibition of herpes simplex virus type 1 infection. Biochem Biophys Res Commun 264, 19-23.PubMedGoogle Scholar
  60. Singh PK, Parsek MR, Greenberg EP, Wilsh MJ. 2002 A component of innate immunity prevents bacterial biofilms development. Nature 417, 552-555.PubMedGoogle Scholar
  61. Stephens S, Dolby JM, Montreuil J, Spik G. 1980 Differences in inhibition of the growth of commensal and enteropathogenic strains of Escherichia coli by lactotransferrin and secretory immunoglobulin A isolated from human milk. Immunology 41, 597-603.PubMedGoogle Scholar
  62. Superti F, Ammendolia MG, Valenti P, Seganti L. 1997 Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT29. Med Microbiol Immunol 186, 83-91.PubMedGoogle Scholar
  63. Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, Antonini G. 2001 Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim Biophys Acta 1528, 107-115.PubMedGoogle Scholar
  64. Tachezy J, Suchan P, Schrevel J, Kulda J. 1998 The host-proteinindependent iron uptake by Tritrichomonas foetus. Exp Parasitol 90, 155-163.PubMedGoogle Scholar
  65. Tanaka K, Ikeda M, Nozaki A et al. 1999 Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C. Jpn J Cancer Res 90, 367-371.PubMedGoogle Scholar
  66. Tanaka T, Omata Y, Narisawa Met al. 1997 Growth inhibitory effect of bovine lactoferrin on Toxoplasma gondii tachyzoites in murine macrophages: role of radical oxygen and inorganic nitrogen oxide in Toxoplasma growth-inhibitory activity. Vet Parasitol 68, 27-33.PubMedGoogle Scholar
  67. Testa V. 2002 Proteins of iron metabolism. Boca Raton: CRC Press: 71-141.Google Scholar
  68. Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi K, Kavase K. 1991 Potent antibacterial peptides generated by pepsin of bovine lactoferrin. J Dairy Sci 74, 4137-4142.PubMedGoogle Scholar
  69. Valenti P, Visca P, Antonini G, Orsi N. 1986 Interaction between lactoferrin and ovotransferrin and Candida cells. FEMS Microbiol Lett 33, 271-275.Google Scholar
  70. Valenti P, Greco R, Pitari G et al. 1999 Apoptosis of Caco-2 intestinal cells invaded by Listeria monocytogenes: protective effect of lactoferrin. Exp Cell Res 250, 197-202.PubMedGoogle Scholar
  71. van der Strate BWA, Beljaars L, Molema G, Harmsen MC, Meijer DKF. 2001 Antiviral activities of lactoferrin. Antiviral Res 52, 225-239.PubMedGoogle Scholar
  72. van Hooijdonk ACM, Kussendrager KD, Steijns JM. 2000 In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence. Br J Nutr 84, S127-S134.PubMedGoogle Scholar
  73. Viani RM, Gutteberg TJ, Lathey JL, Spector SA. 1999 Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS 13, 1273-1274.PubMedGoogle Scholar
  74. Vorland LH. 1999 Lactoferrin: a multifunctional glycoprotein. APMIS 107, 971-981.PubMedGoogle Scholar
  75. Wakabayashi H, Abe S, Teraguchi S, Hayasawa H, Yamaguchi H. 1998 Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 42, 1587-1591.PubMedGoogle Scholar
  76. Wakabayashi H, Hiratani T, Uchida K, Yamaguchi H. 1996 Antifungal spectrum and fungicidal mechanism of an N-terminal peptide of bovine lactoferrin. J Infect Chemother 1, 185-189.Google Scholar
  77. Wakabayashi H, Takakura N, Yamauchi K et al. 2002 Effect of lactoferrin feeding on the host antifungal response in guinea-pigs infected or immunised with Trichophyton mentagrophytes. J Med Microbiol 51, 844-850.PubMedGoogle Scholar
  78. Wakabayashi H, Uchida K, Yamauchi K, Teraguchi S, Hayasawa H, Yamaguchi H. 2000 Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J Antimicrob Chemother 46, 595-660.PubMedGoogle Scholar
  79. Ward PP, Uribe-Luna S, Conneely OM. 2002 Lactoferrin and host defense. Biochem Cell Biol 80, 95-102.PubMedGoogle Scholar
  80. Weinberg ED. 1993 The development of awareness of ironwithholding defense. Perspect Biol Med 36, 215-221.Google Scholar
  81. Weinberg ED. 2001 Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol 53, 1303-1310.Google Scholar
  82. Williams BRG. 2000 Interferons. In: Lederberg J, ed. Encyclopedia of Microbiology. San Diego Academic Press: 2, 826-841.Google Scholar
  83. Yamauchi K, Hiruma M, Yamazaki N et al. 2000 Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43, 197-202.PubMedGoogle Scholar
  84. Yu RH, Schryvers AB. 2000 Bacterial lactoferrin receptors. Insights from characterizing the Moraxella bovis receptors. Biochem Cell Biol 80, 81-90.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Nicola Orsi
    • 1
  1. 1.Department of Public Health SciencesUniversity of Rome `La Sapienza'Italy

Personalised recommendations